Norges Bank’s Travere Therapeutics TVTX Stock Holding History

Norges Bank’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-71,000	Closed	-$1.05M	–	1461
2025 Q2	$1.05M	Hold	71,000	–	–	﹤0.01%	1536
2025 Q1	$1.27M	Hold	71,000	–	–	﹤0.01%	1591
2024 Q4	$1.24M	Hold	71,000	–	–	﹤0.01%	1741
2024 Q3	$993K	Hold	71,000	–	–	﹤0.01%	1728
2024 Q2	$584K	Hold	71,000	–	–	﹤0.01%	1869
2024 Q1	$547K	Hold	71,000	–	–	﹤0.01%	1836
2023 Q4	$638K	Hold	71,000	–	–	﹤0.01%	1891
2023 Q3	$635K	Hold	71,000	–	–	﹤0.01%	1911
2023 Q2	$1.09M	Hold	71,000	–	–	﹤0.01%	1925
2023 Q1	$1.6M	Sell	71,000 -144,000	-67%	-$3.06M	﹤0.01%	1949
2022 Q4	$4.52M	Sell	215,000 -20,900	-9%	-$443K	﹤0.01%	1809
2022 Q3	$5.81M	Buy	235,900 +144,000	+157%	+$3.72M	﹤0.01%	1708
2022 Q2	$2.23M	Buy	+91,900	New	+$2.31M	﹤0.01%	1887
2021 Q1	–	Sell	-24,690	Closed	-$673K	–	2196
2020 Q4	$673K	Hold	24,690	–	–	﹤0.01%	2063
2020 Q3	$456K	Buy	+24,690	New	+$480K	﹤0.01%	2086

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Norges Bank's TVTX Position: Q3 2025 in Review

Norges Bank sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 71,000 shares — an estimated $1.05M sold.

Norges Bank first reported a position in TVTX in Q3 2020 and held it in 15 quarters. The position peaked at $5.81M in Q3 2022. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

Norges Bank reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
Norges Bank sold 71,000 Travere Therapeutics shares in Q3 2025, an estimated $1.05M.
Norges Bank first reported a position in Travere Therapeutics in Q3 2020 and held it in 15 quarters.
Norges Bank's Travere Therapeutics position peaked at $5.81M in Q3 2022.
238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.